DB
VTAE

Dmitry Balyasny’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Dmitry Balyasny’s Portfolio VTAE Stock Details VTAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-301,086
Closed -$3.25M – 1451
2016
Q2 		$3.25M Buy
301,086
+21,930
+8% +$188K 0.02% 598
2016
Q1 		$1.85M Buy
279,156
+163,356
+141% +$1.49M 0.01% 707
2015
Q4 		$2.1M Buy
+115,800
New +$1.59M 0.01% 643

Other funds holding VTAE

AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $449M AUM 51.52% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dmitry Balyasny's VTAE Position: Q3 2016 in Review

Dmitry Balyasny sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q3 2016, closing a stake of 301,086 shares — an estimated $3.25M sold.

Dmitry Balyasny first reported a position in VTAE in Q4 2015 and held it in 3 quarters. The position peaked at $3.25M in Q2 2016. 98 funds tracked by Wall St. Rank hold VTAE as of Q3 2016.

  • Dmitry Balyasny reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q3 2016 after selling out during the quarter.
  • Dmitry Balyasny sold 301,086 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q3 2016, an estimated $3.25M.
  • Dmitry Balyasny first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q4 2015 and held it in 3 quarters.
  • Dmitry Balyasny's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $3.25M in Q2 2016.
  • 98 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q3 2016.

Based on Balyasny Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.